GlassScriptPhysician profile
Shefali Pappu
NPI 1528445947
$2,592.29
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $434 · 2021: $526 · 2022: $679 · 2023: $507 · 2024: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.02 | 2019-2023 | |
| Organon LLC | $174.87 | 2021-2024 | Nexplanon |
| Ethicon US, LLC | $151.05 | 2023-2024 | Ethicon, Echelon; Endopath, Surgicel Nu-Knit |
| Millicent US INC | $136.62 | 2019-2024 | Intrarosa |
| Pfizer INC. | $134.95 | 2022-2024 | |
| Exeltis, USA INC. | $132.14 | 2020-2024 | Slynd |
| Astellas Pharma US INC | $125.53 | 2022-2024 | Veozah |
| Therapeuticsmd, INC. | $115.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.03 | 2019-2022 | |
| Agile Therapeutics, INC. | $80.80 | 2021-2023 | Twirla |
| Myovant Sciences INC. | $71.39 | 2021 | |
| Merck Sharp & Dohme LLC | $67.87 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $50.75 | 2022 | |
| Conmed Corporation | $49.76 | 2022 | |
| Avion Pharmaceuticals | $49.62 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $41.68 | 2022 | |
| Innovation Technologies INC | $36.94 | 2023 | Irrisept |
| Minerva Surgical, INC | $35.95 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $34.68 | 2022 | |
| Potrero Medical, INC. | $34.45 | 2021 | |
| Integra Lifesciences Corporation | $33.88 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Amag Pharmaceuticals, INC. | $32.73 | 2020 | |
| Evofem Biosciences, INC. | $28.43 | 2021-2022 | |
| Lsi Solutions INC | $25.12 | 2020 | |
| Baxter Healthcare | $23.90 | 2024 | Perclot |
| Medtronic, INC. | $20.83 | 2024 | Ligasure |
| Vertical Pharmaceuticals, LLC | $20.54 | 2019 | |
| Sumitomo Pharma America, INC. | $20.52 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $18.86 | 2022 | |
| Zyla Life Sciences, INC. | $17.23 | 2020 | |
| Becton, Dickinson and Company | $16.70 | 2023 | Bd Onclarity |
| Duchesnay USA Incorporated | $15.82 | 2019 | |
| Channel Medsystems, INC. | $15.53 | 2021-2024 | |
| Tela Bio, INC. | $14.24 | 2020 | |
| Boston Scientific Corporation | $13.78 | 2020 | |
| Smith+Nephew, INC. | $13.47 | 2024 | Oasis, Grafix Pl |
| Lupin INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Pappu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.